Aquinox Pharmaceuticals is a technology company.
Aquinox Pharmaceuticals has raised $58.0M across 3 funding rounds.
Aquinox Pharmaceuticals has raised $58.0M in total across 3 funding rounds.
Aquinox Pharmaceuticals has raised $58.0M in total across 3 funding rounds.
Aquinox Pharmaceuticals's investors include Atlas Venture, Highbury Group, Johnson & Johnson Innovation, Kurma Partners, SR One.
Aquinox Pharmaceuticals (NASDAQ: AQXP) was a clinical-stage pharmaceutical company focused on developing targeted therapeutics for inflammation, inflammatory pain, and blood cancers. Founded in 2006 and headquartered in Vancouver, Canada, it raised $65.84M in funding before being acquired by Sun Pharma in July 2020 in an undisclosed deal.[1] The company advanced drug candidates through clinical trials, emphasizing treatments that deliver clinically meaningful outcomes in inflammatory and oncological diseases.[2][3][4]
Note: Aquinox is not a technology company in the software or tech startup sense but a biotech firm leveraging scientific R&D; a current site at aqxpharma.com appears unrelated, operating as an online pharmacy rather than the original entity.[7]
Aquinox Pharmaceuticals emerged in 2006 in Vancouver, Canada, targeting unmet needs in inflammation and cancer treatments.[1][3] Specific founders are not detailed in available records, but the company quickly positioned itself as a clinical-stage player, discovering novel drug candidates and progressing them through 11 clinical trials.[4] Early traction included securing venture funding totaling $65.84M and reaching acquisition by Sun Pharma in July 2020 at the Acq - P2P stage, marking a pivotal exit that integrated its pipeline into a larger pharma entity.[1]
Aquinox rode the biotech wave in inflammation and oncology, where targeted therapies addressed chronic diseases amid rising demand for precision medicine.[1][2][4] Timing aligned with 2010s venture interest in clinical-stage biotechs, fueled by aging populations and cancer prevalence; Vancouver's growing life sciences cluster provided supportive market forces.[3] Post-acquisition by Sun Pharma, its influence persists through pipeline integration, contributing to global pharma innovation rather than standalone tech disruption.[1]
With its 2020 acquisition, Aquinox's independent story concluded, but its assets likely fuel Sun Pharma's inflammation and oncology efforts amid ongoing trends like AI-driven drug discovery and immuno-oncology advances. Future shape depends on Sun Pharma's pipeline progress; expect evolved impact via commercialized therapies rather than new ventures. This biotech trajectory underscores efficient paths from Vancouver startup to global integration, correcting the tech company premise with its true pharmaceutical roots.[1]
Aquinox Pharmaceuticals has raised $58.0M across 3 funding rounds. Most recently, it raised $18.0M Series C in April 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2013 | $18.0M Series C | Atlas Venture, Highbury Group, Johnson & Johnson Innovation, Kurma Partners, SR One | |
| Jun 1, 2010 | $25.0M Series B | Atlas Venture, Highbury Group, Johnson & Johnson Innovation, Kurma Partners, SR One | |
| Jun 1, 2007 | $15.0M Series A | Atlas Venture, Highbury Group, Johnson & Johnson Innovation, Kurma Partners, SR One |